These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27652785)

  • 1. Perspective: Finding common ground.
    Futerman AH; Hardy J
    Nature; 2016 Sep; 537(7621):S160-1. PubMed ID: 27652785
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinsonism, dementia and glucocerebrosidase mutations.
    Peall K; Robertson NP
    J Neurol; 2013 May; 260(5):1441-4. PubMed ID: 23620067
    [No Abstract]   [Full Text] [Related]  

  • 3. Involvement of Gaucher Disease Mutations in Parkinson Disease.
    Vilageliu L; Grinberg D
    Curr Protein Pept Sci; 2017; 18(7):758-764. PubMed ID: 26965692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
    Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
    J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaucher and Parkinson diseases: unexpectedly related.
    Rogaeva E; Hardy J
    Neurology; 2008 Jun; 70(24):2272-3. PubMed ID: 18541881
    [No Abstract]   [Full Text] [Related]  

  • 6. A lysosomal lair for a pathogenic protein pair.
    Dawson TM; Dawson VL
    Sci Transl Med; 2011 Jul; 3(91):91ps28. PubMed ID: 21753118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
    Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
    Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.
    Ginns EI; Mak SK; Ko N; Karlgren J; Akbarian S; Chou VP; Guo Y; Lim A; Samuelsson S; LaMarca ML; Vazquez-DeRose J; Manning-Boğ AB
    Mol Genet Metab; 2014 Feb; 111(2):152-62. PubMed ID: 24388731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of lysosomal storage disorders as illustrated by Gaucher disease.
    Aerts JM; Van Weely S; Boot R; Hollak CE; Tager JM
    J Inherit Metab Dis; 1993; 16(2):288-91. PubMed ID: 8411983
    [No Abstract]   [Full Text] [Related]  

  • 10. The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.
    Toffoli M; Smith L; Schapira AHV
    J Neurochem; 2020 Jul; 154(1):11-24. PubMed ID: 31965564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
    Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
    Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gaucher disease].
    Eto Y
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():317-21. PubMed ID: 11347084
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
    Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
    J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological looping in the synucleinopathies: investigating the link between Parkinson's disease and Gaucher disease.
    Kinghorn KJ
    Dis Model Mech; 2011 Nov; 4(6):713-5. PubMed ID: 22065839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saposin C protects glucocerebrosidase against α-synuclein inhibition.
    Yap TL; Gruschus JM; Velayati A; Sidransky E; Lee JC
    Biochemistry; 2013 Oct; 52(41):7161-3. PubMed ID: 24070323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.
    Meivar-Levy I; Horowitz M; Futerman AH
    Biochem J; 1994 Oct; 303 ( Pt 2)(Pt 2):377-82. PubMed ID: 7980395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gaucher disease: insights from a rare Mendelian disorder.
    Sidransky E
    Discov Med; 2012 Oct; 14(77):273-81. PubMed ID: 23114583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Xilouri M; Brekk OR; Stefanis L
    Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease.
    Wei J; Takamatsu Y; Wada R; Fujita M; Ho G; Masliah E; Hashimoto M
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33672048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.
    Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH
    Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.